Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Molecular Partners

< Previous 1 2 Next >
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners and Orano Med Announce Co-Development Agreement for Radio-DARPin Therapies
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS)
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation Summit
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Interim Management Statement Q3 2023: Continued Validation Seen Across the DARPin Portfolio
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents New Data on its Radio DARPin Therapy (RDT) Platform at the EANM 2023 Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Reports H1 2023 Corporate Highlights and Financials
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation Summit
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 ASCO Annual Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Participate in RBC Capital 2023 Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Interim Management Statement Q1 2023 of Molecular Partners: Well Capitalized to Pursue Highly Differentiated DARPin Portfolio Strategy
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present Additional Preclinical Data Supporting the Company’s Radio DARPin Therapy Platform at AACR
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Shareholders Approve All Board Proposals at the Annual General Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Publishes Invitation to Annual General Meeting 2023
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Hold Conference Call to Discuss Fourth Quarter and Full Year 2022 Results and Present at the 43rd Annual Cowen Health Care Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents New Preclinical Data Supporting Its Radio DARPin Therapy Platform
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners to Present at SVB Leerink Global Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Presents New Preclinical Data Supporting its MP0533 DARPin T-Cell Engager for the Treatment of AML
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Acceptance of Oral Presentation at the Annual American Society of Hematology Meeting
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Molecular Partners Announces Upcoming Participation in Investor and Scientific Conferences
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
Interim Management Statement Q3 2022: Continued Progress Across Oncology Programs with First Clinical Data Expected from Phase 1 Trial of MP0317 and Initiation of Phase 1 Trial of MP0533 Anticipated by Year-End
From Molecular Partners
Via GlobeNewswire
Tickers MOLN
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.